Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million

GlobeNewswire

Dublin, Oct. 15, 2026 -- "Saudi Arabia Non-Invasive Prenatal Testing Market Report by Component, Application, End User, Cities and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.

Saudi Arabia Non-Invasive Prenatal Testing Market Outlook

According to the report, the Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to increase from US$ 52.50 Million in 2025 to US$ 162.16 Million by 2034. The market is expected to register a Compound Annual Growth Rate (CAGR) of 13.35% from 2026 to 2034, supported by increasing prenatal health awareness, rising maternal age, advances in molecular diagnostics and continued investment in healthcare infrastructure.

Demand for early and accurate screening of fetal chromosomal abnormalities is increasing across the Kingdom. Greater access to specialized maternal healthcare, genetic counseling and advanced laboratory services is also strengthening the adoption of Non-Invasive Prenatal Testing. Government healthcare initiatives, precision medicine programs and the expansion of preventive screening are expected to create further opportunities for laboratories, hospitals and technology providers.

Key Saudi Arabia NIPT Market Growth Drivers

Technological advancement remains a central market driver. Improvements in next-generation sequencing (NGS), molecular diagnostics, bioinformatics and laboratory automation have enhanced the accuracy, reliability and scope of prenatal genetic screening. Advanced platforms increasingly support screening for Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), sex chromosome abnormalities, microdeletions and selected inherited conditions. Faster processing, reduced testing errors and improved workflow efficiency are helping healthcare institutions expand their prenatal screening capabilities.

Rising maternal age is also contributing to demand. Social and economic changes, including higher educational attainment, career development and evolving family planning preferences, have increased the number of pregnancies among women in their thirties and later. As chromosomal abnormality risks rise with maternal age, healthcare professionals are increasingly recommending accurate prenatal risk assessment, particularly for high-risk pregnancies.

Saudi Arabia's prevalence of genetic and inherited disorders is encouraging greater emphasis on preventive healthcare and early screening. NIPT adoption is expanding among patients with a family history of inherited conditions, previous pregnancy complications or other clinical risk factors. Continued investment in genetic testing capacity and specialized maternal care is expected to support sustained market development.

Market Challenges

Limited awareness and uneven access to genetic counseling remain important barriers. Some expectant parents lack sufficient information about the clinical value, capabilities and limitations of NIPT, which can delay decision-making or reduce participation in prenatal screening programs. Differences in healthcare knowledge and service availability between regions may also lead to unequal adoption. Expanded patient education, healthcare provider engagement and access to qualified counseling will be important for broader market penetration.

Instruments and Services

The Saudi Arabia NIPT instruments market is benefiting from increased investment in next-generation sequencing systems, polymerase chain reaction (PCR) platforms, sample preparation equipment and bioinformatics solutions. Hospitals, diagnostic laboratories and specialized genetic testing centers are modernizing their capabilities to improve analytical accuracy, processing speed and laboratory efficiency.

The services segment is expanding as prenatal genetic screening becomes more integrated into maternal care. Specialized diagnostic laboratories, maternity centers and hospitals are increasing access to testing and counseling, while improved turnaround times are strengthening patient and physician confidence. Hospitals are expected to remain a major end-user segment because of their role in patient consultation, sample collection, clinical follow-up and pregnancy management.

Down syndrome screening represents a significant application within the Saudi Arabia Non-Invasive Prenatal Testing market. Rising maternal age, stronger prenatal health awareness and improved access to genetic testing are increasing demand for Trisomy 21 risk assessment. Screening for Edwards syndrome, Patau syndrome, Turner syndrome and other chromosomal conditions also contributes to market expansion.

Programs and Competitive Developments

King Faisal Specialist Hospital & Research Centre has expanded preventive fetal screening and advanced prenatal genomics programs using NIPT and NGS technologies. These initiatives are strengthening screening capacity and supporting the detection of a broader range of genetic diseases. The Saudi NIPT Expert Consortium has also supported a national adoption roadmap intended to encourage wider implementation across healthcare institutions.

International companies are expanding technologies, testing portfolios and laboratory support within the Saudi market. Active participants include Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., Centogene NV and Qiagen. Competitive activity includes sequencing-based NIPT deployment, prenatal testing service expansion, molecular diagnostic workflow development and broader availability of screening panels through regional healthcare providers.

Regional Market Highlights

Riyadh is expected to remain Saudi Arabia's largest and most advanced NIPT market. The capital benefits from a concentration of specialist hospitals, maternity centers, diagnostic laboratories and professionals trained in prenatal genetics and fetal medicine. Public and private healthcare investment continues to improve access to advanced molecular diagnostics and prenatal screening services.

Jeddah is another major market, supported by an extensive network of hospitals, maternity clinics and private healthcare providers. Collaboration between healthcare institutions and diagnostic laboratories is improving the availability and timeliness of genetic testing. The city's large and diverse population is expected to sustain demand for prenatal screening.

Dhahran and Dammam are emerging NIPT markets in the Eastern Province. Dhahran benefits from modern medical facilities, corporate healthcare programs, specialized clinics and growing access to genetic counseling. Dammam's expanding hospital and diagnostic center network is supporting the integration of genetic screening into prenatal care. Healthcare modernization, patient education and laboratory investment are expected to drive continued growth in both cities.

Saudi Arabia NIPT Market Segmentation

  • Component: Instruments, Kits and Reagents, and Services
  • Application: Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome, and Other Applications
  • End User: Hospitals and Diagnostic Labs
  • Cities: Riyadh, Jeddah, Dammam, Dhahran, Jubail, Khobar, Tabuk, Mecca, Medina, and Rest of Cities

The report evaluates key market participants through company overviews, key personnel, recent developments, SWOT analysis and revenue analysis. Overall, Saudi Arabia's focus on healthcare modernization, early diagnosis and precision medicine is expected to strengthen the role of Non-Invasive Prenatal Testing in maternal and fetal healthcare through 2034.

Report AttributeDetails
No. of Pages200
Forecast Period2025 - 2034
Estimated Market Value (USD) in 2025$52.5 Million
Forecasted Market Value (USD) by 2034$162.16 Million
Compound Annual Growth Rate13.3%
Regions CoveredSaudi Arabia

Key Topics Covered:

1. Introduction

2. Research Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Saudi Arabia Non-Invasive Prenatal Testing Market

6. Market Share Analysis
6.1 Component
6.2 Application
6.3 End User
6.4 Cities

7. Component - Historical and Current Market Trends & Forecast
7.1 Instruments
7.2 Kits and Reagents
7.3 Services

8. Application - Historical and Current Market Trends & Forecast
8.1 Down Syndrome (Trisomy 21)
8.2 Edwards Syndrome (Trisomy 18)
8.3 Patau Syndrome (Trisomy 13)
8.4 Turner Syndrome
8.5 Other Applications

9. End User - Historical and Current Market Trends & Forecast
9.1 Hospitals
9.2 Diagnostic Labs

10. Cities - Historical and Current Market Trends & Forecast
10.1 Riyadh
10.2 Jeddah
10.3 Dammam
10.4 Dhahran
10.5 Jubail
10.6 Khobar
10.7 Tabuk
10.8 Mecca
10.9 Medina
10.10 Rest of Cities

11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes

12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat

13. Merger and Acquisition

14. Key Players Analysis
14.1 Eurofins Scientific
14.1.1 Overviews
14.1.2 Key Person
14.1.3 Recent Developments
14.1.4 SWOT Analysis
14.1.5 Revenue Analysis
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Overviews
14.2.2 Key Person
14.2.3 Recent Developments
14.2.4 SWOT Analysis
14.2.5 Revenue Analysis
14.3 Invitae Corporation
14.3.1 Overviews
14.3.2 Key Person
14.3.3 Recent Developments
14.3.4 SWOT Analysis
14.3.5 Revenue Analysis
14.4 Illumina Inc.
14.4.1 Overviews
14.4.2 Key Person
14.4.3 Recent Developments
14.4.4 SWOT Analysis
14.4.5 Revenue Analysis
14.5 Natera Inc.
14.5.1 Overviews
14.5.2 Key Person
14.5.3 Recent Developments
14.5.4 SWOT Analysis
14.5.5 Revenue Analysis
14.6 Centogene NV
14.6.1 Overviews
14.6.2 Key Person
14.6.3 Recent Developments
14.6.4 SWOT Analysis
14.6.5 Revenue Analysis
14.7 Qiagen
14.7.1 Overviews
14.7.2 Key Person
14.7.3 Recent Developments
14.7.4 SWOT Analysis
14.7.5 Revenue Analysis
Companies Featured

  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Invitae Corporation
  • Illumina Inc.
  • Natera Inc.
  • Centogene NV
  • Qiagen

For more information about this report visit https://www.researchandmarkets.com/r/3obv06

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. ESFI Shares Electrical Safety Considerations For Severe StormsSevere Storms Pose Unique Electrical Hazards to Both Homes and Businesses
  2. FinanceFort Technology Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price RequirementFort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort” or the “Company”), today announced that on October 13, 2026, it received a written notification (the “Notification”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
  3. FinanceDime Commercial Bancshares, Inc.Dime Commercial Bancshares to Release Earnings on October 20, 2026Dime Commercial Bancshares to Release Earnings on October 20, 2026
  4. FinanceKingstone CompaniesKingstone Schedules Third Quarter 2026 Earnings Release and Conference CallKingstone Companies, Inc. (Nasdaq: KINS) ("Kingstone" or the "Company"), a regional property and casualty insurance holding company, today announced that it will issue financial results for the third quarter ended September 30, 2026, after the market closes on Thursday, November 5, 2026.
  5. FinanceZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on October 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 74,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
  6. Picton Mahoney Asset ManagementPicton Mahoney Asset Management Announces Monthly Distribution for PICTON Long Short Income Alternative Fund Exchange Traded Fund Units, PICTON Credit Opportunities Alternative Fund Exchange Traded Fund Units, PICTON Core Bond Fund Exchange Traded Fund Units, PICTON Multi-Strategy Alpha Alternative Fund Exchange Traded Fund Units and PICTON Investment Grade Alternative Fund Exchange Traded Fund Units(TSX: PFIA, PFCO, PFCB, PFAA, PFIG) Picton Mahoney Asset Management (“PICTON Investments”) announced today that it has declared the October 2026 monthly cash distribution of $0.0587 per unit for the ETF units (“ETF Units”) of the PICTON Long Short Income Alternative Fund.